Stockreport

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

NeuroSense Therapeutics Ltd.  (NRSN) 
PDF CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel [Read more]